TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06253871: A Phase 1/1b Study of IAM1363 in HER2 Cancers

Sponsor: Iambic Therapeutics, Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 383 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT06253871 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06253871 Rescue Dossier →